Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 11 to 20 of 86

TitleReference numberPublishedLast updated
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTG696
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017

Results per page

  1. 10
  2. 25
  3. 50
  4. All